Archimedes acquires chitosan IP for intranasal drug delivery
This article was originally published in Scrip
Executive Summary
The UK drug delivery company Archimedes Development, a subsidiary ofArchimedes Pharma, has acquired the intellectual property for a range of chitosan derivatives from the Finnish firm Fennopharma.